Literature DB >> 31632824

Heterogeneity of stage IIIA leads to difficulty in determining optimal treatment.

Min P Kim1, Stephen G Swisher2.   

Abstract

Year:  2019        PMID： 31632824      PMCID： PMC6783775          DOI： 10.21037/jtd.2019.08.111

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

1.  The significance of one-station N2 disease in the prognosis of patients with nonsmall-cell lung cancer.

Authors:  Panagiotis Misthos; Evangelos Sepsas; John Kokotsakis; Ion Skottis; Achilleas Lioulias
Journal:  Ann Thorac Surg       Date:  2008-11       Impact factor: 4.330

2.  Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Kristel Vandormael; Antonio Riccio; Jing Yang; M Catherine Pietanza; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2019-01-08       Impact factor: 44.544

3.  Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

Authors:  J A Roth; E N Atkinson; F Fossella; R Komaki; M Bernadette Ryan; J B Putnam; J S Lee; H Dhingra; L De Caro; M Chasen; W K Hong
Journal:  Lung Cancer       Date:  1998-07       Impact factor: 5.705

4.  Modern outcome and risk analysis of surgically resected occult N2 non-small cell lung cancer.

Authors:  Hyun Jin Cho; Sung Ryong Kim; Hyeong Ryul Kim; Jin-Ok Han; Yong-Hee Kim; Dong Kwan Kim; Seung-Il Park
Journal:  Ann Thorac Surg       Date:  2014-04-24       Impact factor: 4.330

5.  Which subgroup of patients with pathologic N2 non-small cell lung cancer benefit from surgery?

Authors:  Yasunobu Funakoshi; Yukiyasu Takeuchi; Hidenori Kusumoto; Toru Kimura; Hajime Maeda
Journal:  J Cancer Res Clin Oncol       Date:  2012-02-25       Impact factor: 4.553

6.  Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial.

Authors:  R Rosell; J Gómez-Codina; C Camps; J Javier Sánchez; J Maestre; J Padilla; A Cantó; A Abad; J Roig
Journal:  Lung Cancer       Date:  1999-10       Impact factor: 5.705

7.  Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.

Authors:  Jan P van Meerbeeck; Gijs W P M Kramer; Paul E Y Van Schil; Catherine Legrand; Egbert F Smit; Franz Schramel; Vivianne C Tjan-Heijnen; Bonne Biesma; Channa Debruyne; Nico van Zandwijk; Ted A W Splinter; Giuseppe Giaccone
Journal:  J Natl Cancer Inst       Date:  2007-03-21       Impact factor: 13.506

8.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takayasu Kurata; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Corinne Faivre-Finn; Martin Reck; Johan Vansteenkiste; David R Spigel; Catherine Wadsworth; Giovanni Melillo; Maria Taboada; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

9.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

Authors:  Kathy S Albain; R Suzanne Swann; Valerie W Rusch; Andrew T Turrisi; Frances A Shepherd; Colum Smith; Yuhchyau Chen; Robert B Livingston; Richard H Feins; David R Gandara; Willard A Fry; Gail Darling; David H Johnson; Mark R Green; Robert C Miller; Joanne Ley; Willliam T Sause; James D Cox
Journal:  Lancet       Date:  2009-07-24       Impact factor: 79.321

10.  Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).

Authors:  Wilfried Ernst Erich Eberhardt; Christoph Pöttgen; Thomas Christoph Gauler; Godehard Friedel; Stefanie Veit; Vanessa Heinrich; Stefan Welter; Wilfried Budach; Werner Spengler; Martin Kimmich; Berthold Fischer; Heinz Schmidberger; Dirk De Ruysscher; Claus Belka; Sebastian Cordes; Rodrigo Hepp; Diana Lütke-Brintrup; Nils Lehmann; Martin Schuler; Karl-Heinz Jöckel; Georgios Stamatis; Martin Stuschke
Journal:  J Clin Oncol       Date:  2015-11-02       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.